1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Demographic features of participants
Demographics (No.) (%) Age (mean) (SD) (yr) 49.2 (10.6) Male sex 6 (60%) WHO grade III 7 (70%) IV 3 (30%) Extent of resection Biopsy 2 (20%) Subtotal 3 (30%) Gross total 5 (50%) IDH1/2 mutational status IDH wild-type 4 (40%) IDH mutant 6 (60%) MGMT promoter methylation status Unmethylated 4 (40%) Methylated 4 (40%) Unknown 2 (20%) Concurrent TMZ (median) (range) (% completed) 100% (80%–100%) Adjuvant TMZ (median) (range) (No. of cycles) 6 (6–12)
Note:—IDH indicates isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA methyltransferase; TMZ, temozolomide.